Serina Therapeutics Welcomes New Leadership in Chemistry
In a strategic move to bolster its leadership team, Serina Therapeutics, Inc. (NYSE American: SER), a pioneering clinical-stage biotechnology company, has appointed Dr. Joshua Thomas as its Vice President and Head of Chemistry. Dr. Thomas brings a wealth of experience and expertise, particularly in the development of cutting-edge drug candidates. This significant appointment reflects Serina's commitment to advancing its investigational drug, SER-252, aimed at addressing advanced Parkinson's disease using its proprietary POZ Platform technology.
Dr. Thomas's Background and Expertise
A Leader in Drug Development
Prior to joining Serina, Dr. Thomas honed his skills through various leadership roles at Mersana Therapeutics. His 13 years there were marked by his critical contributions to the development of discovery chemistry capabilities and innovative drug delivery systems. One of his key achievements includes the development of a novel STING agonist antibody-drug conjugate (ADC) platform. Dr. Thomas has led extensive research programs that are pivotal to the evolution of antibody drug conjugates, particularly in harnessing unique mechanisms of action for targeted cancer therapies.
Significance of the Appointment
Steve Ledger, the Chief Executive Officer of Serina Therapeutics, expressed that working with Dr. Thomas over the past two years had already proven valuable, stating, "Bringing his demonstrated talent and leadership fully on board as VP and Head of Chemistry is a natural step as we push the boundaries of our small molecule opportunity." His insight will greatly enhance Serina's initiatives, aiming to expand its POZ platform into new therapeutic areas.
Serina's Vision and the POZ Platform
Serina Therapeutics focuses on developing drug product candidates that address neurological disorders, leveraging its proprietary POZ Platform technology. This innovative approach offers substantial potential to improve the efficacy and safety profiles of various drug modalities, including small molecules and RNA-based therapeutics. Serina aims to harness the strengths of the POZ technology to create groundbreaking therapies for patients in need.
Future Developments with SER-252
SER-252, an investigational therapy formulated using the POZ platform, aims to deliver continuous dopaminergic stimulation (CDS) to patients with Parkinson’s disease. Early preclinical studies show promise in mitigating the side effects typically associated with standard treatments, offering hope for those affected by this debilitating condition. As Serina prepares to advance SER-252 into clinical trials soon, the leadership change reflects a broader strategy to deepen its research and development capabilities.
About Serina Therapeutics
Serina Therapeutics is an emerging biotechnology firm dedicated to developing a portfolio of innovative therapeutic candidates. Their headquarters, situated in Huntsville, Alabama, serves as a hub for advancing research and technology in the realm of polymer-enabled therapeutics. By integrating advanced drug delivery systems with well-established therapeutics, Serina aims to address critical unmet needs in treatment.
About the POZ Technology
The POZ technology utilized by Serina involves a synthetic polymer that enhances drug delivery mechanisms. This system enables more efficient drug loading and release management, particularly beneficial for medications with challenging pharmacokinetic profiles. Utilizing this platform, Serina is poised to revolutionize how medications are delivered, ensuring that drugs maintain therapeutic levels longer in the bloodstream.
Frequently Asked Questions
What is Serina Therapeutics focused on?
Serina Therapeutics is dedicated to developing drug candidates for neurological diseases, using innovative technologies like the POZ platform.
What qualifications does Dr. Joshua Thomas have?
Dr. Thomas holds a Ph.D. in Medicinal Chemistry and has extensive experience in drug development, particularly in chemistry and bioconjugation systems.
What is the significance of the POZ Platform?
The POZ Platform allows for enhanced control over drug delivery systems, improving the efficacy and safety profiles of various therapeutic modalities.
What is SER-252 and its intended use?
SER-252 is an investigational apomorphine therapy designed to provide continuous dopaminergic stimulation to help manage Parkinson's disease symptoms.
Where is Serina Therapeutics based?
Serina Therapeutics is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology.
